Lui Franciosi, PhD
Dr. Franciosi has more than 20 years of experience conducting pharmaceutical and medical device studies in academia and industry. Previously, he acted as the Chief Operating Officer at Verona Pharma PLC, London Stock Exchange (AIM: VRP). Prior to Verona Pharma, Dr. Franciosi completed his post-doctoral research in COPD progression modeling at the Clinical Pharmacology & Discovery Medicine Unit, GlaxoSmithKline, UK. He obtained his Doctorate & Masters degrees at The University of British Columbia (UBC), Canada – and pursued business studies at the University of Warwick, UK. He is currently an adjunct professor at UBC Faculty of Medicine, Department of Anesthesiology, Pharmacology & Therapeutics.
David AlexanderMr. Alexander holds a Bachelor of Commerce in Finance from The University of British Columbia. His past achievements include; CFO of Arakis Energy Corporation, an international oil and gas development company, and managed the company’s growth from startup to over a billion dollars in assets, leading to a listing on the NASDAQ market. Arakis was subsequently sold to Talisman Energy. David was also CFO of Nortran Pharmaceuticals, Inc., a UBC based pharmaceutical company engaged in the development and commercialization of cardiovascular therapies. While at Nortran, David helped secure initial and ongoing research financing. Nortran ultimately became Cardiome Pharma, a successful Vancouver B.C. based pharmaceutical company (Nasdaq: CRME).
Donald R. Carlow, MD
Dr. Carlow was the past President and CEO (Jan 1994 – Oct 2000) of the British Columbia Cancer Agency (BCCA). Dr. Carlow’s efforts led to the development of new cancer centers, as well as laying the groundwork for the BC Cancer Research Center. Dr. Carlow was a member of the board of the Vancouver Island Health Authority, where he chaired the board’s health quality committee for four years. He proposed the establishment of the BC Council on Quality and Safety. Additionally, he acted as a judge for the 3M National Health Care Quality Awards for four years during the 90’s.
Ms. Sampson is an international marketing and sales professional, having practiced in South Africa, Europe, the US and Canada. She brings a dynamic energy, a wealth of talent, and a multi-layered business expertise to the Company. She is a business start-up professional, with a history of ground-up to successful ventures. An accomplished sales professional, marketer, designer, developer with international experience, she brings superior business branding skills and internal administration expertise to Veritas. Ms. Sampson is currently President of Marapharm Ventures Inc. Marapharm is a developmental stage publicly traded medical marijuana company with operations based in British Columbia; Nevada and Washington in the United States.
Yari Nieken, MBA
Mr. Nieken has a wide range of public company and capital market experience. He is Founder and President of Foremost Capital Inc. an Exempt Market Dealer. He is currently a director of Marapharm Ventures Inc. and has served on the boards of several public and private issuers including PUF Ventures (President & CEO), Lexagene Holdings Inc. (Director), Duport Capital Ltd (Director) and has raised substantial capital in his career. He holds an MBA from the Sydney Graduate School of Management and a BA from the University of British Columbia. He was formerly an investment advisor at Union Securities Corp. and continues to be a registrant in good standing in the provinces of British Columbia, Alberta, and Ontario.